LY2228820 (Dimesylate), 5mg

A trisubstituted imidazole derivative supplied by STEMCELL Technologies as the dimesylate salt, this compound acts as a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) and is reported to have anti-inflammatory and anti-neoplastic activities. Provided as a crystalline solid with a stated purity of ≥ 98% and a molecular weight of 612.7 g/mol, the substance is also known by the synonyms Ralimetinib Mesylate and LSN2322600 and carries CAS number 862507-23-1. It is intended for laboratory research use only.

According to the manufacturer's product information, published applications include maintenance and self-renewal of hematopoietic stem cells, where LY2228820 has been combined with other small molecule inhibitors to enhance self-renewal of cord blood-derived cells, as well as cancer research, where inhibition of p38 MAPK is associated with reduced tumor growth in animal models of various human cancers. The product is stable at -20°C as supplied and should be protected from prolonged exposure to light; for long-term storage, use of a desiccant is recommended. Solubility guidance is supplied for water (≤ 200 mM), DMSO (≤ 55 mM), and absolute ethanol (≤ 4.8 mM), with a recommendation to prepare stock solutions fresh before use and to avoid final DMSO concentrations above 0.1% in cell culture due to potential cell toxicity.

The safety data sheet states that the substance is not classified as hazardous under the 2012 OSHA Hazard Communication Standard or the Globally Harmonized System (GHS), and no specific exposure limits are listed. Recommended handling follows good industrial hygiene and safety practice, with storage in tightly closed containers in a dry, cool, and well-ventilated place.